Feed AXSM
AX

Axsome Therapeutics AXSM · NASDAQ

$161.79 -0.27% (-$0.43)

Market cap
$8.33B
Enterprise value
$8.23B
P/E
-
Forward P/E
-
PEG
-
P/S
10.7x
P/FCF
-
EV/EBITDA
-
ROIC
-50.9%
Gross margin
93.2%
Net margin
-24.7%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
0.60
Free float
84.3%

About the company

Axsome Therapeutics, Inc. (AXSM) is a biotechnology company focused on the development and commercialization of innovative drugs for the treatment of various neurologic and psychiatric disorders. The company targets therapeutic areas such as depression, migraines, Alzheimer's disease, and other neurological conditions that have a significant impact on human health. Axsome Therapeutics aims to improve the quality of life for patients by offering novel and effective treatment options. With active research and clinical trials, the company has a promising pipeline of drugs that can have a positive impact on healthcare and the medical industry. Investing in Axsome Therapeutics, Inc. (AXSM) shares can be an attractive choice for investors who follow the biotechnology and pharmaceutical sectors and seek a company with the potential for significant growth and innovative treatment approaches.

Sector

Healthcare

Industry

Biotechnology

CEO

Herriot Tabuteau

Employees

1,346

Headquarters

New York City

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.